July 17, 2023. ZURICH and CAMBRIDGE, Mass. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the appointment of Jakob Vowinckel, Ph.D., as Chief Officer of Scientific Operations (COSO).
Having joined Biognosys in 2016, Jakob has excelled in various roles of increasing responsibility for Biognosys’ contract research service operations. Throughout his tenure, he co-authored numerous peer-reviewed publications and abstracts on the application of proteomics in biomarker discovery and drug development. As Head of Discovery Proteomics, he led a dedicated team that empowered countless biopharma and biomarker customers to accelerate and de-risk their research and development through unbiased proteomics. Jakob also led the development of Biognosys’ novel data exploration tool, Proteoverse™.
In his new capacity, Jakob assumes responsibility for all contract research activities in both Switzerland and the US. Additionally, he will continue to oversee Biognosys’ data insights offerings. Jakob succeeds Chief Operating Officer Karel Novy, who decided to pursue a different career direction after having served Biognosys for seven years in different roles. Karel played a pivotal role in the growth and success of the company. We thank him for his outstanding contributions to the organization and wish him all the best for his future.
“I am thrilled to take on this role at an unprecedented time of international growth for Biognosys,” commented Biognosys’ incoming Chief Officer of Scientific Operations Jakob Vowinckel, Ph.D. “With our team of dedicated scientists, we will continue to best serve our customers’ needs for deep and high-throughput proteomics research solutions that yield actionable insights for life science research and drug development. With the inauguration of our new research facility in the US later this year, we will significantly enhance the accessibility and convenience of our services for international customers.”
“The Chief Officer of Scientific Operations position is responsible for delivering on our mission to make the proteome actionable by providing leading-edge, accessible, and reliable solutions for life science research and ensuring industry-leading quality standards in our contract research services,” said Oliver Rinner, Ph.D., CEO and co-founder of Biognosys. “I am pleased to have a strong internal talent stepping up into this role with Jakob and delighted to welcome him to our executive management team.”
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07